• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Bye-Bye China?

    Decentralized Trials Fuel AI Revolution in Clinical Research

    Self-Medication: Flexibility for Patients and Drug Manufacturers

    The Single-Use Mixing Landscape: Evaluating Your Options

    DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    KORSCH, MEDELPHARM Partner on R&D Equipment Portfolio

    Frontage Bolsters Clinical Services Capabilities

    Sanofi Unveils EUROAPI as Name of New European API Company

    Thermo Fisher Buys Novasep's Viral Vector Manufacturing Biz

    Precision Medicine Group Acquires Project Farma
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Sanofi Unveils EUROAPI as Name of New European API Company

    Precision Medicine Group Acquires Project Farma

    Cytiva Delivers Modular Biologics Factory to Lonza

    Fujifilm, CABIM Get $76M Funding for Mfg. and Innovation Center

    LSNE Expands Fill Finish and Lyophilization Ops
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Catalent Acquires Acorda’s INBRIJA Manufacturing Operations

    Varcode, PL Developments Form Strategic ‘Smart Tag’ Pact

    COVID-19 Vaccine Distribution: The Air Cargo Industry’s Greatest Challenge

    Thermo Fisher Expands Clinical Supply Services in Europe

    Schreiner MediPharm Joins DoseID Consortium
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Virtual Clinical Trials: The Future of Dermatology Studies

    Frontage Bolsters Clinical Services Capabilities

    Thermo Fisher Buys Novasep's Viral Vector Manufacturing Biz

    Precision Medicine Group Acquires Project Farma

    Cytiva Delivers Modular Biologics Factory to Lonza
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Gene Therapy Co. Selects ValGenesis' SaaS Platform

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    CDMO Cognate BioServices Teams Up with L7 Informatics

    Samsung Biologics Adopts Veeva Vault QMS to Unify Quality Management

    The Wasdell Group Earns ISO 13485 Certification
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Adare Pharma Solutions

    Cytovance Biologics

    Baxter BioPharma Solutions

    Syngene

    Reed-Lane
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    PCI Pharma Services

    Syngene

    Alcami

    Adare Pharma Solutions

    Baxter BioPharma Solutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Online Exclusives

    Evaluating Pharma Amid COVID-19

    Dr. Ural of Ernst & Young LLP discusses market dynamics, enduring therapeutic areas, near term M&A, and how industry can use this time for transformation

    Evaluating Pharma Amid COVID-19
    Arda Ural, Ph.D., EY Americas Industry Markets Leader, Health Sciences and Wellness
    Related CONTENT
    • Biologics Development & Manufacturing
    • Virtual Clinical Trials: The Future of Dermatology Studies
    • Frontage Bolsters Clinical Services Capabilities
    • Thermo Fisher Buys Novasep's Viral Vector Manufacturing Biz
    • Chemical Development
    Kristin Brooks, Contract Pharma05.18.20

    While the pharmaceutical industry is less susceptible to market dynamics during a downturn as compared to other industries, this unpredictable environment amid the COVID-19 pandemic has pharma rethinking their portfolios and pipeline assets, supply chains, API sourcing, and manufacturing.

    Arda Ural, Ph.D., a Principal and the Americas Industry Markets Leader, Health Sciences and Wellness at Ernst & Young LLP, provides insights on market dynamics, enduring therapeutic areas, near term M&A for pharma/biopharma, and how industry can use this time for transformation in commercial, supply chain and product development. –KB

    Contract Pharma: How are pharma/biopharma companies adjusting their portfolios as a result of the pandemic?

    Arda Ural: COVID-19 has meant biopharma companies’ must reconsider their portfolios, prioritizing how to secure the performance of in-market products and re-thinking assets currently in the development pipeline.

    As it relates to in-market products, companies have been exploring supply chain initiatives to pre-empt any disruption by securing their APIs and excipients. They are also forecasting demand for specific products based on the elasticity for each therapeutic area. We recommend a dynamic and scenario-driven forecasting methodology and increasing the number of sales and operational planning sync-ups between manufacturing and commercial functions to adjust to this highly unpredictable environment. Of note, commercial teams are pivoting to digital channels, given sales’ inability to meet in-person with target providers.

    Companies are also closely assessing their pipeline. COVID-19 has already impacted the pace of patient enrollment in clinical trials. As a result, the net present value of these pipeline assets may have changed, leading to a reshuffling of portfolio priorities. We are aware of several companies who are re-optimizing their pipeline as a result of COVID-19. Our recommendation to clients is to analyze the full portfolio immediately in a scenario-based approach and keep refreshing it on a monthly and quarterly basis.

    Finally, companies with a viable candidate for a diagnostic tool, treatment or vaccine for COVID-19 have prioritized all their developmental activities to bring it to the market. While it’s a pressing imperative for the public good, this also asserts the company as a leader in fighting COVID-19. 

    CP: How are sponsors responding to new challenges conducting research and clinical trials? 

    AU: The COVID-19 outbreak has made it difficult for pharmaceutical companies to recruit patients for new trials and to keep already-enrolled patients compliant with protocols to avoid invalidation of the study outcomes.

    Studies suggest that approximately 56% of U.S. clinical research study sites and 81% of European sites are less likely to continue current enrolled clinical trials and comply with study protocols and schedules.1 At this point, more than 30 pharma/biopharma companies have reported a clinical trial disruption due to COVID-19. Some companies have paused clinical trial enrollment, uncertain about the ability to access testing sites. In parallel, trials for therapeutics and vaccines for COVID-19 have been expedited. A silver lining of this pandemic may be the much-needed acceleration of the digitalization and simplification of clinical trials. Addressing these cumbersome processes is long-overdue. 

    Biopharma companies spend approximately 17% of its revenue on R&D activities. This number has been consistently increasing over the last decade and is mostly driven by large and expensive later-stage clinical trials.  

     Additionally, we anticipate three potential benefits for sponsors as a result of COVID-19:

    •          First, they may increase adoption of telehealth technologies, thereby enabling virtual visits, reducing patient travel and lowering dropouts.
    •          Second, we foresee an increase in remote patient monitoring to bolster patient safety. By some estimates, 70% of patients enrolled currently live at least two hours away from their trial site.2 
    •         Lastly, remote trial operations may significantly lower expenses. Digital capabilities could accelerate enrollment and enable improved retention and quality audits through electronic or video  consent platforms and would offer remote site monitoring solutions.

    CP: Which therapeutic areas are likely to endure the coming downturn?

    AU: Several therapeutic areas have shown an increase in demand due to managing COVID-19 infections. These include antibiotics, antivirals, respiratory nebulizers and inhalers, analgesics and anaesthetics used in acute care and intensive care settings. In fact, the sharp spike in their demand coupled with the disruption of the supply chain led to worldwide shortages. It should be noted that most of the medications in these therapeutic areas are commoditized.

    Specialty therapeutics, including those for oncology, hematology and auto-immune diseases (e.g., multiple sclerosis, rheumatoid arthritis, psoriasis and diabetes) have mostly maintained their utilization. This may shift in the near future, since most companies have seen an uptick due to pre-emptive buy-in by wholesalers to accommodate anticipated demand.

    The location of care of services is also a critical variable. Therapies that can be administered at home or at ambulatory surgical centers are less affected.

    On the other hand, companies that rely on newly diagnosed patients to grow their products in these therapeutic areas are expecting a slow-down due to lack of access to primary care physicians who prioritized COVID-19 patients over non-emergency visits.

    Finally, therapies for less acute needs, including ophthalmology, dermatology, gastroenterology, infertility treatments, life-style treatments, products for asymptomatic cardiovascular conditions and vaccines that are not related to COVID-19 may experience an adverse impact. The patients in these therapeutic areas may not actively seek care or renew prescriptions, and demand may drop. 

    CP: What do you anticipate in the near term for pharma/biopharma M&A?

    AU: M&A activity in 2019 demonstrated an all-time high transactions value at $370 billion, in which the lack of at-scale assets pushed up valuations.  In contrast to $147 billion worth of transactions in the first three months of 2019, the comparable period in 2020 only resulted $22 billion in capital deployment.

    By studying three prior recessionary periods, we concluded that the life sciences industry is less susceptible to market dynamics during a downturn when compared to other industries, as measured by M&A volume. Specifically, in 1991, life sciences deal volume grew 54% while deal volume for all other sectors combined declined by 2.4%. In 2001, life sciences deal volume grew 18%. Deal volume for all other sectors declined by 32%. Finally, in 2008, life sciences deal volume declined by 25%, but that was still better than the 30% decline in deal activity for all other sectors.

    The uncertainty COVID-19 ushered in will impact M&A across the industry. First, companies may use their balance sheets to preserve cash. These reserves would be used to finance their operations at a priority over other capital deployments including M&A, stock buybacks or dividends. Additionally, the ability to forecast and value the acquisition or divestiture of assets in this environment may be challenging.

    However, when we polled life sciences executives, nearly half said they would consider M&A activity in the next 12 months. We believe this is driven by a few tailwinds, starting with the systemic need to replenish the pipeline with late stage assets. Biopharma has been challenged by an intrinsic R&D productivity and needs to maintain its growth by acquiring biotech assets.

    Additionally, the industry is experiencing $160 billion worth of exclusivity loss through 2023, and the lost revenue needs to be supplemented by acquiring highly de-risked or in-market assets. A precipitous drop in targets’ values may encourage some opportunistic acquisitions.

    It is also worth mentioning that the collective dry powder of the biopharma industry remains at $1 trillion as of March 2020—slightly down from $1.2 trillion at the end of last year, but still at a formidable level. As a comparison, private equity maintains $1.4 trillion capital ready to deploy.

    In summary, while 2020 looks to be a relatively slow year, we believe the biopharma M&A activity may be resilient when compared to other industries. Our prediction is supported by past observations in prior recessions, underlying industry trends and liquidity on the side-lines.

    CP: What lasting impact do you anticipate COVID-19 will have on life sciences in the months and years ahead? 

    AU: This pandemic facilitated an unprecedented market environment which will compel the industry to reimagine and reinvent itself.

    Starting with commercial, the industry may rely more heavily on digital and telemedicine platforms. Companies could be more willing to try new business models and rely less on traditional distribution and payment schemes.

    We expect governments may provide strong guidelines to re-patriate manufacturing of some essential medications in the next 12 months, thus positively impacting supply chains. These regulations will likely require pharma companies to nimbly reshape their supply chain footprint, think differently about their API and excipient sourcing and develop compliance mechanisms. These adjustments may partially reverse the trend of globalization and outsourcing of the supply chain to lower cost geographies.

    Finally, as we discussed earlier, the industry could fundamentally reimagine its traditional approach to the end-to-end clinical trial process. This would require significant digitalization and simplification in areas ranging from adoption of telehealth technologies to remote patient consent, patient monitoring and site monitoring.

    Although this pandemic has been a global disruptor, the industry should leverage this moment as an accelerator to trigger transformation in commercial, supply chain and product development.
     


    [1] Continuum Clinical report

    [2] Andy Coravos of Elekra Labs
     


    Arda is a Principal and the Americas Industry Markets Leader, Health Sciences and Wellness at Ernst & Young LLP in New York with a focus on the Life Sciences sector. Prior to joining EY, he was a Managing Director at a strategy consulting firm for six years, where he led the Life Sciences M&A Practice. Earlier, he worked as a VP of Strategic Marketing and a BU Lead at an American medical technology company. He also served as the SVP Marketing & Sales for a startup biotechnology company which went public.

    Related Searches
    • Clinical Trials
    Suggested For You
    The Future of Clinical Trials Series: Part II The Future of Clinical Trials Series: Part II
    The Future of Clinical Trials Series: Part I The Future of Clinical Trials Series: Part I
    Biologics Development & Manufacturing Biologics Development & Manufacturing
    Virtual Clinical Trials: The Future of Dermatology Studies Virtual Clinical Trials: The Future of Dermatology Studies
    Frontage Bolsters Clinical Services Capabilities Frontage Bolsters Clinical Services Capabilities
    Thermo Fisher Buys Novasep Thermo Fisher Buys Novasep's Viral Vector Manufacturing Biz
    Chemical Development Chemical Development
    Precision Medicine Group Acquires Project Farma Precision Medicine Group Acquires Project Farma
    Charles River Partners with JADE Charles River Partners with JADE
    Cytiva Delivers Modular Biologics Factory to Lonza Cytiva Delivers Modular Biologics Factory to Lonza
    Fujifilm, CABIM Get $76M Funding for Mfg. and Innovation Center Fujifilm, CABIM Get $76M Funding for Mfg. and Innovation Center
    LSNE Expands Fill Finish and Lyophilization Ops LSNE Expands Fill Finish and Lyophilization Ops
    Pharmaceutical and Biotherapeutic Development and Testing Pharmaceutical and Biotherapeutic Development and Testing
    RheinCell Therapeutics Achieves GMP Certification RheinCell Therapeutics Achieves GMP Certification
    EVOQ Therapeutics and Amgen Partner EVOQ Therapeutics and Amgen Partner

    Related Online Exclusives

    • Clinical Trials | Drug Development | Information Technology
      Advancing Digital Endpoints in Clinical Trials

      Advancing Digital Endpoints in Clinical Trials

      An end-to-end approach to managing wearable devices through clinical development.
      Kristin Brooks, Contract Pharma 12.14.20

    • Clinical Trials | Drug Development | Preclinical Outsourcing
      Accelerating R&D Trends

      Accelerating R&D Trends

      The pandemic has propelled lingering trends into the forefront and increasingly complex molecules and biologics have drug developers outsourcing more.
      Kristin Brooks, Contract Pharma 10.20.20

    • Clinical Trials
      Impact of COVID-19 on Winning New Business

      Impact of COVID-19 on Winning New Business

      WuXi Clinical’s Vice President of Biometrics, David Ng, talks about the impact of COVID-19 on clinical trials and business relations
      Tim Wright, Editor, Contract Pharma 06.03.20


    • Clinical Trials
      Pioneering Medicine Forward

      Pioneering Medicine Forward

      May 20th marks Clinical Trials Day, celebrating 273 years of clinical trials
      Tina Bland, Senior Consultant, KCR Trial Execution Consulting 05.18.20

    • Clinical Trials | CRO News | Drug Development | Information Technology | R&D
      CRO Industry Update

      CRO Industry Update

      Serge Bodart of IDDI provides insight on the pharma and biopharma trends impacting CROs, outsourcing in today’s market, and advances in clinical research.
      Kristin Brooks, Contract Pharma 04.27.20

    • Clinical Trials | Information Technology | QA/QC
      Managing Clinical Trials Amid the Coronavirus Pandemic

      Managing Clinical Trials Amid the Coronavirus Pandemic

      Patrick Hughes of CluePoints discusses the impact on clinical trials and how leveraging data may herald a long overdue paradigm shift in the industry.
      Kristin Brooks, Contract Pharma 04.06.20


    • Biologics, Proteins, Vaccines | cGMP Manufacture | Clinical Trials | Drug Development | Scale-up/Technology Transfer
      Rapid Delivery of Medical Countermeasures Amid Pandemic

      Rapid Delivery of Medical Countermeasures Amid Pandemic

      Robert Erwin of iBio discusses the company’s COVID-19 vaccine development efforts and FastPharming manufacturing platform for the rapid delivery of vaccines
      Kristin Brooks, Contract Pharma 04.03.20

    • Biologics, Proteins, Vaccines | Clinical Trials | Drug Development
      COVID-19 Vaccine Response

      COVID-19 Vaccine Response

      ICON execs discuss developments in vaccine research efforts and key challenges of delivering a coronavirus vaccine
      Kristin Brooks, Contract Pharma 04.01.20

    • Biologics, Proteins, Vaccines | Breaking News | Clinical Trials | Drug Development
      COVID-19 Clinical Trials

      COVID-19 Clinical Trials

      The vaccines in development for COVID-19, who's developing them, and where they stand in the development process
      Kristin Brooks, Contract Pharma 03.10.20


    • Clinical Trials | Drug Development | R&D
      Rare Disease R&D

      Rare Disease R&D

      Finding the hard-to-reach and leveraging big data and machine learning in drug development
      Kristin Brooks, Contract Pharma 02.25.20

    • Biologics, Proteins, Vaccines | Clinical Trials | Drug Development | Industry News
      Outsourcing in the Cell & Gene Therapy Space

      Outsourcing in the Cell & Gene Therapy Space

      Specialized and coordinated capabilities aim to accelerate drug development and reduce risk for sponsors
      Kristin Brooks, Contract Pharma 02.04.20

    • Clinical Trials | CRO News | Drug Development | Industry News | Information Technology
      Janssen, PRA Design First Mobile Virtual Trial

      Janssen, PRA Design First Mobile Virtual Trial

      Kent Thoelke and Greg Licholai of PRA discuss the alliance, advances that have made virtual clinical trials possible, and the obstacles that remain
      Kristin Brooks, Contract Pharma 01.06.20


    • Clinical Trial Materials | Clinical Trials | Information Technology
      Contract Pharma’s 20th Anniversary Series: Clinical Supply

      Contract Pharma’s 20th Anniversary Series: Clinical Supply

      Technology plays a big role in clinical trials, supplies, and the rise of patient-centricity
      Kristin Brooks, Contract Pharma 10.29.19

    • Clinical Trials | CRO News | Drug Development | Information Technology | R&D
      Contract Pharma’s 20th Anniversary Series: CRO Perspective

      Contract Pharma’s 20th Anniversary Series: CRO Perspective

      Randy Marchbanks of PPD discusses how CRO operations have evolved to accommodate changing industry needs
      Kristin Brooks, Contract Pharma 10.28.19

    • Clinical Trials | Information Technology
      Clinical Trial Technology

      Clinical Trial Technology

      The use of new technology to monitor and manage clinical trials.
      Ricky Lakhani, Director of Product Management, PHARMASEAL 10.25.19

    Trending
    • Fujifilm To Invest $2B In US Manufacturing Site
    • Roche Canada To Invest $500M To Create 500 Jobs In Ontario
    • Tonix And Fujifilm Enter COVID-19 Vax Deal
    • Sanofi Unveils EUROAPI As Name Of New European API Company
    • Sorrento, Mount Sinai To Develop COVI-Shield Antibody Therapy
    Breaking News
    • KORSCH, MEDELPHARM Partner on R&D Equipment Portfolio
    • Frontage Bolsters Clinical Services Capabilities
    • Sanofi Unveils EUROAPI as Name of New European API Company
    • Thermo Fisher Buys Novasep's Viral Vector Manufacturing Biz
    • Precision Medicine Group Acquires Project Farma
    View Breaking News >
    CURRENT ISSUE

    November/December 2020

    • Modeling Process Safety Workflows in Pharmaceutical Manufacturing Scale-Up
    • Ensuring Quality During the Transfer and Scale Up of Rx Drugs
    • Inspecting the Unexpected
    • Cold Chain Trends
    • Catering for the Complex
    • Biopharma Contract Manufacturing: Robust Growth Ahead
    • DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    • The Single-Use Mixing Landscape: Evaluating Your Options
    • Self-Medication: Flexibility for Patients and Drug Manufacturers
    • Decentralized Trials Fuel AI Revolution in Clinical Research
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Brown Fat Associated with Reductions in Chronic Disease Risk
    NIH Study Identifies Antibacterial Properties in Taurine
    NSF Begins New Certification Program
    Coatings World

    Latest Breaking News From Coatings World

    Zeppelin Acquires MTI Mischtechnik
    Ezio Braggio Joins ChemQuest Europe
    IFS Coatings Announce Carbon Offset Program
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Optimize EP Launches CaRM Cardiac Device Data Management Platform
    U.S. TAVR Market Projected to Reach Nearly $5 Billion by 2030
    FDA Clears Canon Medical's Compressed SPEEDER for 3D Exams on 1.5T MR
    Contract Pharma

    Latest Breaking News From Contract Pharma

    KORSCH, MEDELPHARM Partner on R&D Equipment Portfolio
    Frontage Bolsters Clinical Services Capabilities
    Sanofi Unveils EUROAPI as Name of New European API Company
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Neenah to Host Packaging Webinar for Printers
    W.S. Badger is Named a ‘150 Top Impact Company’
    Mana Products, Meiyume and RPG Form The Vertical Beauty Alliance
    Happi

    Latest Breaking News From Happi

    A Surge in Interest for Supplements & Vitamins
    P&G, L'Oréal & Amorepacific Make News at CES
    Three Form Vertical Beauty Alliance
    Ink World

    Latest Breaking News From Ink World

    dar-tech, inc. Becomes U.S. Midwestern Distributor for ZS Interpolymer
    Techkon USA, Konica Minolta Partner
    Alon Bar-Shany Appointed Chairman of Highcon Board
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Exhibitor registration opens for virtual.drupa
    FTA planning in-person Forum & INFOFLEX
    Fortis Solutions Group achieves SGP certification
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Shemesh Adds U.S. Headquarters
    TZMO USA, Special Needs Group Form Partnership
    BAHP Announces 2021 Officers, Board of Directors
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Rapid Recovery Protocol Can Lead to Increased Range of Motion After TKA
    Boston Scientific Releases WaveWriter Alpha Spinal Cord Stimulators in U.S.
    New Chief Clinical Officer on Board at IncludeHealth
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Roadsimple Modernizes Warehouse Ops with Zebra Technologies
    Toppan Announces 2050 Environmental Vision
    SOI Industry Consortium Joins SEMI as Strategic Association Partner

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login